Trevena Inc TRVN

Healthcare Biotechnology

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).

OTCPK:TRVN - Post by User

Trevena Inc

Bullboard Posts

Post by ERTguyon Feb 15, 2017 12:47am

66 Views

Post# 25847148

I can't let you be the only poster here Gekko

Otherwise you'd be talking to yourself ;-). I will be honest here though. I see a scenario for a near term test of $7 based on both the MACD about to cross downward, and this was the price level from the ascending triangle breakout on January 30th. If this scenario plays out here I will by stock at this level, partly based on fundamentals but mostly on technical. These health care plays make me nervous, even though I bought PLI yesterday LOL. Cheers

Bullboard Posts

Gold vs. bitcoin, where should you invest?